PCN46 COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY- A SENSITIVITY ANA ...
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)74297-2
https://www.valueinhealthjournal.com/article/S1098-3015(10)74297-2/fulltext
Title :
PCN46 COST SAVINGS RELATED TO SUPERIOR ADVERSE EVENT PROFILE OF BEVACIZUMAB PLUS CHEMOTHERAPY VERSUS CETUXIMAB PLUS CISPLATIN/VINORELBINE IN THE FIRST-LINE THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY- A SENSITIVITY ANA ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)74297-2&doi=10.1016/S1098-3015(10)74297-2
First page :
Section Title :
Open access? :
No
Section Order :
227